Objective To study the clinical effect of aripiprazole combined with lithium carbonate in the treatment of acute mania .Methods 72 patients with acute mania were selected in this research .According to the order of admission,the patients with odd numbers were selected as the control group (n=36),and the patients with even numbers were selected as the observation group (n=36).The control group was treated with clozapine combined with lithium carbonate ,the observation group was treated by aripiprazole combined with lithium carbonate .The safety and efficacy of the treatment were evaluated by BRMS score , effective rate , incidence rate of adverse reaction etc .Results After treatment for 1 week,2 weeks,the BRMS scores of the observation group were (21.23 ±2.22)points and (20.02 ±2.12)points,which were significantly lower than those of the control group (t=4.0390,4.0025,all P<0.05).After treatment for 4 and 8 weeks,the BRMS scores of the two groups were similar .The effective rate of the observation group was 94.44%,which of the control group was 91.67%,the difference was not statistically signifi-cant (P>0.05).The incidence rate of adverse reactions of the observation group was 19.44%,which was significantly lower than 41.67% of the control group,the difference was statistically significant (χ2 =11.6446,P<0.05) .Conclusion Aripiprazole combined with lithium carbonate has similar effect with clozapine combined with lithium carbonate in the treatment of acute mania ,but the combination therapy of aripiprazole and lithium carbonate can effec -tively alleviate the symptoms of the disease ,and with less adverse reaction ,high safety,which can be promoted and applicated in clinical .

Objective:To investigate the clinical efficacy of psychotherapy combined with early comprehensive rehabilitation therapy in the treatment of acute cerebral infarction and the possible mechanism of action.Methods:Eighty-four patients with acute cerebral infarction who received treatment in Yuhang Fifth People's Hospital, China between June 2018 and February 2020 were included in this study. They were randomly divided into an observation group ( n = 44) and a control group ( n = 40). The control group was treated with conventional therapy. The observation group was subjected to early comprehensive rehabilitation therapy combined with psychotherapy based on conventional therapy. All patients were treated for 1 month. Clinical efficacy, the percentage of highly glycosylated type I transmembrane glycoprotein-positive cells and vascular endothelial growth factor receptor-2-positive cells (CD 34+KDR +) in monocytes, and serum level of stromal cell-derived factor-1α were compared between the observation and control groups. Results:After treatment, the scores of Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) and National Institutes of Health Stroke Scale (NIHSS) were (16.4 ± 3.8) points, (17.9 ± 5.2) points, (3.56 ± 0.46) points, respectively, which were significantly lower than those in the control group [(23.4 ± 5.6) points, (23.7 ± 6.4) points, (5.39 ± 0.87) points, t = 7.896, 7.258, 6.935, all P < 0.05]. Barthel Index, Fugl-Meyer score, and Functional Independence Score in the observation group were (79.7 ± 20.8) points, (54.6 ± 17.2) points, (96.8 ± 8.5) points, respectively, which were significantly higher than those in the control group [(60.4 ± 17.6) points, (39.6 ± 14.8) points, (83.1 ± 9.7) points, t = 8.123, 7.251, 8.009, all P < 0.05]. After treatment, the percentage of CD34 +KDR + in monocytes and serum level of stromal cell-derived factor-1α in the observation group were (1.58 ± 0.19)% and (1.84 ± 0.11) μg/L, respectively, which were significantly higher than those in the control group [(0.73 ± 0.20)% and (1.34 ± 0.09) μg/L, t = 7.125, 6.983, both P < 0.05). Conclusion:Based on conventional treatment, psychotherapy combined with early rehabilitation treatment can improve the clinical efficacy in the treatment of acute cerebral infarction possibly through increasing the percentage of CD 34+KDR + in monocytes and the serum level of stromal cell-derived factor-1α.